Wealth Science Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.38M Sell
2,645
-85
-3% -$43.5K 0.58% 25
2026
Q2
$1.36M Buy
2,730
+694
+34% +$308K 0.6% 27
2026
Q1
$923K Hold
2,036
– – 0.52% 24
2025
Q4
$923K Hold
2,036
– – 0.53% 24

Other funds holding VRTX

Wealth Science Advisors's VRTX Position: Q3 2026 in Review

Wealth Science Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 3.1% in Q3 2026, selling an estimated $43.5K and leaving 2,645 shares worth $1.38M. The position accounts for 0.58% of the portfolio, ranked #25.

Wealth Science Advisors first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. 1,796 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Wealth Science Advisors held 2,645 shares of Vertex Pharmaceuticals worth $1.38M as of Q3 2026.
  • Wealth Science Advisors sold 85 Vertex Pharmaceuticals shares in Q3 2026, an estimated $43.5K.
  • Vertex Pharmaceuticals made up 0.58% of Wealth Science Advisors's portfolio in Q3 2026, its #25 holding.
  • Wealth Science Advisors first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 1,796 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Wealth Science Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.